Navigation Links
TorkLaw Continuing to Accept DePuy ASR Hip Implant Cases - Deadline Approaching January 6, 2014
Date:12/27/2013

LOS ANGELES, Dec. 27, 2013 /PRNewswire/ -- In November 2013, Johnson & Johnson announced that it has agreed to pay at least $2.5 billion to settle nearly 8,000 DePuy Orthopaedics Hip Implant lawsuits which have been filed across the country.  It is estimated by some accounts that the total settlement figure could reach $4 billion.

The settlement will focus on cases stemming from injuries caused to patients by the recalled DePuy ASR hip system.  The more than 8,000 potential injured victims had to have had revision or corrective surgery prior to August 31, 2013. 

The deadline to register a claim to be a part of this settlement is January 6, 2014.

"We are urging victims of the DePuy hip system to contact us as soon as possible to determine if they are eligible to be a part of the settlement," said Reza Torkzadeh, Founder of The Torkzadeh Law Firm.

The settlement will be handled in two phases.  Victims must first register before the deadline.  They then have until April 1, 2014 to "opt-in."  Once a victim has become a part of the settlement, a baseline value of $250,000.00 per claimant has been set aside.  From there, each claimant will be evaluated independently based on injuries, medical bills, history and other various damages that each victim has suffered.  Additional compensation may then be awarded.

"There are over 12,000 lawsuits filed across the country against Johnson & Johnson for the defective DePuy hip implant.  These metal-on-metal devices are very dangerous and have caused some serious and permanent injuries to victims across the country.  This settlement will help some, but not all of the victims who have been impacted by DePuy.  We intend on litigating
'/>"/>

SOURCE The Torkzadeh Law Firm
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. TorkLaw Accepting St. Jude Medical Device Cases
2. TorkLaw Accepting DePuy Hip Implant Cases
3. TorkLaw Responds to FDA Warning Letter to St. Jude Medical Regarding Defective Heart Device; Now Representing Patients in 15 States
4. Herborium Announces Continuing Progress In Key Strategic Initiatives
5. China Health Resource Reports on Record Year-End 2011 Results Continuing Strong in 2012
6. EPIC Pharmacies offers members discounted access to online continuing education course - Management & HR Skills for Pharmacists
7. New Research Shows Continuing Medical Education Saves Healthcare Costs
8. MSA Announces Record Continuing Sales and Operating Income
9. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
10. Attention Veterans: New Medtech Job Training Program Accepting Applications through Friday, August 31
11. Pennsylvania State Police to Accept Expired, Unwanted Prescription Medications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 27, 2015 Bronstein, Gewirtz & Grossman, LLC ... the securities of Celladon Corporation ("Celladon" or the "Company") ... Peretz Bronstein or his investor relations coordinator ... 212-697-6484. The investigation concerns whether Celladon and ... 10(b) and 20(a) of the Securities Exchange Act of ...
(Date:4/27/2015)... 27, 2015 Vermillion, Inc. (VRML), ... disease, announced today it will report first ... close on Monday, May 11, 2015, followed ... at 4:30pm Eastern.Conference Call & Webcast: Monday, ... Domestic: , 888-556-4997International: , 719-457-2628Conference ID: , ...
(Date:4/27/2015)... , April 27, 2015  Novira Therapeutics, Inc., a ... curative treatment of chronic hepatitis B virus (HBV) infection, ... its lead HBV core inhibitor candidate, NVR 3-778, at ... the Study of the Liver (EASL) in ... of NVR 3-778 from studies performed in a humanized ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Celladon Corporation 2Novira Therapeutics Announces Presentation of Preclinical Antiviral Data for NVR 3-778 at EASL 2Novira Therapeutics Announces Presentation of Preclinical Antiviral Data for NVR 3-778 at EASL 3
... 2011 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... and commercialization of products for central nervous system disorders, ... one of Israel,s leading private biotech, pharmaceutical and medical ... Israel. "We are excited to reach this ...
... Cell Therapeutics, Inc. ("CTI") (NASDAQ: CTIC ... that final results from the phase II OPAL study ... acute myeloid leukemia (AML) were presented by Jorge Cortes, ... Center during the Acute Myeloid Leukemia - Therapy, excluding ...
Cached Medicine Technology:Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 2Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 3Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 4Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 2Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 3Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 4
(Date:4/27/2015)... According to a recent report from ... chronic back pain, TMJ disorders are the second ... disability. In addition, the report revealed that TMJ disorders ... costing an estimated 4 billion dollars annually. , These ... seemingly unrelated symptoms such as headaches, neck pain, tenderness ...
(Date:4/27/2015)... Thanks to a $7.5 million grant from ... institutions, including American University, will operate in a new ... behavioral research aimed at ending the AIDS epidemic. , ... HIV or AIDS, according to the latest statistics. At ... over the age of 13 was living with HIV, ...
(Date:4/27/2015)... April 27, 2015 Doctors on Liens ... on a lien basis for over twenty years. So when ... the best doctor in the Fresno area , Doctors ... DC and his team of medical specialists. With a ... massage therapist, Dilanchian Chiropractic is now helping more ...
(Date:4/27/2015)... Church, VA (PRWEB) April 27, 2015 ... Integrity Issues Within Your Operations or Your Partners/Suppliers, **FDAnews ... p.m. EDT, http://www.fdanews.com/DataIntegrity , Data integrity issues ... the last few years., Uncovering data integrity issues within ... once data integrity issues come to light, remediating them ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 FMC Corporation’s ... exhibit its wide range of market leading ingredients and ... 7 in Geneva, Switzerland. Vitafoods Europe 2015 expects to ... countries showcasing the latest research in such areas as ... , FMC Health and Nutrition’s booth will feature ...
Breaking Medicine News(10 mins):Health News:Dentist in Graham NC Reveals that a Jaw Disorder May Be the Cause of Chronic Headaches and Back Pain 2Health News:D.C. Center for AIDS Research Established with New Grant from NIH 2Health News:D.C. Center for AIDS Research Established with New Grant from NIH 3Health News:Eminent Doctor Joins Forces with Doctors on Liens in Fresno 2Health News:FDAnews Announces — Data Integrity Problems on the Rise: Confronting Data Integrity Issues Within Your Operations or Your Partners/Suppliers Webinar, May 19, 2015 2Health News:FDAnews Announces — Data Integrity Problems on the Rise: Confronting Data Integrity Issues Within Your Operations or Your Partners/Suppliers Webinar, May 19, 2015 3Health News:FDAnews Announces — Data Integrity Problems on the Rise: Confronting Data Integrity Issues Within Your Operations or Your Partners/Suppliers Webinar, May 19, 2015 4Health News:FMC Health and Nutrition to Feature Epax® Brand Omega-3 Ingredients at Vitafoods Europe 2015 2
... ... some people have questioned if the HCG diet can be harmful. Dr Robert True addresses ... , ... Dr. Robert sees patients on a daily basis that he helps lose weight through his ...
... ... BtoB companies seeking a proven approach for lead cultivation with social media. , ... Portland, OR (PRWEB) March 24, 2010 -- ... Five Ways to Leads: How BtoBs Should Use Social Media , a complimentary Webinar event ...
... This release is available in Spanish . ... same area as the original tumour remains the strongest, independent ... who have been free of disease for a very long ... European Breast Cancer Conference (EBCC7). Dr Sven Mieog, MD, ...
... available in Spanish . Barcelona, Spain: ... goal in survival with new treatment should be to prolong ... might expect from using current best therapies, a researcher will ... today (Wednesday). This finding contrasts with doctors, perception that an ...
... the Barcelona Public Health Agency has revealed those sections of ... published in the journal Respiratory Research , shows that ... aged over 50 or infected with HIV. "Some patients ... of six months), resulting in a danger of them infecting ...
... the death of a loved one can provide much-needed consolation ... study in the April issue of the Journal of ... a relative to cancer took part in the study. Participants ... widows, widowers, daughters and sisters. Nine chose foot massage, eight ...
Cached Medicine News:Health News:HCG True Diet – Dr. Robert True Speaks About the Importance of Medical Supervision for HCG Diets 2Health News:Webinar Shares Proven Social Media Approach to BtoB Lead Generation 2Health News:Recurrence of breast cancer after more than 10 years is an important indicator of survival 2Health News:Recurrence of breast cancer after more than 10 years is an important indicator of survival 3Health News:What should be the goal of treatment in metastatic breast cancer? 2Health News:What should be the goal of treatment in metastatic breast cancer? 3Health News:Older people and those with HIV are more vulnerable to tuberculosis 2Health News:Hand and feet massages provide consolation for bereaved relatives 2
... patented ratchet design provides fingertip ratchet disengagement ... I Instrument program offers state-of-the-art quality in ... maintaining strength and durability. Low profile cutting ... joint spaces. Series I instruments are available ...
... ratchet design provides fingertip ratchet disengagement allowing ... Instrument program offers state-of-the-art quality in an ... strength and durability. Low profile cutting tips ... spaces. Series I instruments are available in ...
... patented ratchet design provides fingertip ratchet disengagement ... I Instrument program offers state-of-the-art quality in ... maintaining strength and durability. Low profile cutting ... joint spaces. Series I instruments are available ...
... A broad selection of procedurally specific ... and allow easy access to all ... variety of approaches.,Loop Handled Graspers feature ... holds tissue firmly without tearing or ...
Medicine Products: